<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052922</url>
  </required_header>
  <id_info>
    <org_study_id>3R01CA121125-03S1</org_study_id>
    <nct_id>NCT01052922</nct_id>
  </id_info>
  <brief_title>Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement</brief_title>
  <official_title>Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ancillary Aim #1 We will evaluate intervention effects by comparing binary outcomes for&#xD;
      screening (yes/no) in the primary SOS study. In this aim, we propose to calculate actual&#xD;
      screening rates by use of time-to-event analyses (also known as survival analysis). The&#xD;
      outcome variable of interest is the first time since randomization to have CRCS, either based&#xD;
      on FOBT, FS, or CS. Knowing screening rates will not only enable us to make comparisons&#xD;
      between groups, but also over time.&#xD;
&#xD;
      Ancillary Aims #2 and #3 We will recruit additional participants for two ancillary study&#xD;
      aims. First, we will enroll patients age 50-74 years using the same criteria as for the&#xD;
      primary SOS study, which includes neither history of colorectal cancer nor evidence of&#xD;
      life-limiting disease. Participants who return the questionnaire, consent and considered&#xD;
      eligible will be randomized to receive one of three different at-home fecal test kits. The&#xD;
      kits will be returned to the GH centralized laboratory, and participants will be informed&#xD;
      about lab results using standard GH pathways. Participants who have a test-positive will&#xD;
      receive a series of two follow-up surveys (first at 1-2 weeks post result and second at&#xD;
      4-months post result). A comparison group of test-negative results will be matched based on&#xD;
      selected criteria, and this group will also receive the follow-up surveys. Participants at&#xD;
      both time intervals who do not return the survey via mail will be called and if available,&#xD;
      administered the questionnaire via phone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to FOBT test kit</measure>
    <time_frame>1-2 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2260</enrollment>
  <condition>Colorectal Cancer Screening</condition>
  <arm_group>
    <arm_group_label>2 sample InSure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1 sample OC-Micron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 sample g-SENSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3 sample g-SENSA</intervention_name>
    <description>Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.</description>
    <arm_group_label>3 sample g-SENSA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 sample InSure</intervention_name>
    <description>Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.</description>
    <arm_group_label>2 sample InSure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1 sample OC-Micron</intervention_name>
    <description>Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.</description>
    <arm_group_label>1 sample OC-Micron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Not up to date on CRCS&#xD;
&#xD;
          -  Continuously enrolled in GHC for 24 months&#xD;
&#xD;
          -  Expected to continue to be enrolled at GHC for 24 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known high risk for CRC&#xD;
&#xD;
          -  History of CRC&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  Current anticoagulation therapy&#xD;
&#xD;
          -  Organ failure&#xD;
&#xD;
          -  Serious illness&#xD;
&#xD;
          -  Debilitating disease&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Nursing home resident.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly B Green, MD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Washinton Health Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Mass Screening</keyword>
  <keyword>Population Surveillance</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Occult Blood</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>Sigmoidoscopy</keyword>
  <keyword>Health Behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

